Tech Company Financing Transactions
ImmusanT Funding Round
On 12/13/2011, ImmusanT landed $20 million in Series A funding from Vatera Healthcare Partners.
Transaction Overview
Company Name
Announced On
12/13/2011
Transaction Type
Venture Equity
Amount
$20,000,000
Round
Series A
Investors
Vatera Healthcare Partners (Sundar Kodiyalam)
Proceeds Purpose
The proceeds will fund the Nexvax2 therapeutic and diagnostic development plan to the point of demonstrating proof-of-concept. ImmusanT expects to initiate the next clinical trial in early 2012.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
1 Kendall Sq. Building 700
Cambridge, MA 02139
USA
Cambridge, MA 02139
USA
Phone
Website
Email Address
Overview
ImmusanT is a biotechnology company focused on developing a treatment, and a set of diagnostic and monitoring tools to manage patients with celiac disease.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Leslie Williams
Chief Medical Officer
Kenneth Truitt
Chief Scientific Officer
Robert Anderson
Vice President
Joyce Pinkham
VP - Bus. Development
Matan Dabora
VP - Finance
Jonathan Yeadon
VP - Operations
Kristin Neff
Browse more venture capital transactions:
Prev: 12/12/2011: LiveWire Mobile venture capital transaction
Next: 12/13/2011: xAD venture capital transaction
Share this article
News on VC Transactions
Our team works diligently to document every notable VC transaction. VC investment data records reported here are sourced from a variety of public sources. The information is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs